Cargando…

TRIB3 rs6037475 is a potential biomarker for predicting felodipine drug response in Chinese patients with hypertension

BACKGROUND: Our previous studies have found that single nucleotide polymorphisms (SNPs) of tribbles homolog 3 (TRIB3) are related to the hypotensive effects of calcium-channel blockers (CCBs) and angiotensin-converting enzyme (ACE) inhibitors. In this study, we aimed at exploring and validating the...

Descripción completa

Detalles Bibliográficos
Autores principales: He, Fazhong, Sun, Bao, Li, Ling, Liu, Mouze, Lin, Weijie, Liu, Lin, Sun, Yinxiang, Luo, Yuhong, Wu, Lin, Lu, Ligong, Zhang, Wei, Zhou, Zhiling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7210142/
https://www.ncbi.nlm.nih.gov/pubmed/32395481
http://dx.doi.org/10.21037/atm.2020.03.176
_version_ 1783531220205830144
author He, Fazhong
Sun, Bao
Li, Ling
Liu, Mouze
Lin, Weijie
Liu, Lin
Sun, Yinxiang
Luo, Yuhong
Wu, Lin
Lu, Ligong
Zhang, Wei
Zhou, Zhiling
author_facet He, Fazhong
Sun, Bao
Li, Ling
Liu, Mouze
Lin, Weijie
Liu, Lin
Sun, Yinxiang
Luo, Yuhong
Wu, Lin
Lu, Ligong
Zhang, Wei
Zhou, Zhiling
author_sort He, Fazhong
collection PubMed
description BACKGROUND: Our previous studies have found that single nucleotide polymorphisms (SNPs) of tribbles homolog 3 (TRIB3) are related to the hypotensive effects of calcium-channel blockers (CCBs) and angiotensin-converting enzyme (ACE) inhibitors. In this study, we aimed at exploring and validating the effect of TRIB3 polymorphism on antihypertensive drugs responses. METHODS: A total of 830 hypertensive patients, who were administered with open-labeled hydrochlorothiazide (12.5 mg once daily) and randomly assigned to off-labeled felodipine (5 mg) or a matched placebo combination treatment (1:1), were selected from the Felodipine Event Reduction (FEVER) study. A strategy of screening 259 samples and validating the remaining 531 samples was implemented. Four functional SNPs were selected (rs2295490, rs11470129, rs4815567 and rs6037475 in TRIB3). A mixed linear model was performed to analyze the effects of TRIB3 SNPs on antihypertensive drugs responses. RESULTS: We found that TRIB3 rs6037475 CC genotype was associated with a reduction of diastolic blood pressure (DBP) (P=6.3×10(−3)) in the felodipine treatment group of screening set, and was also associated with a reduction of systolic blood pressure (SBP) (P=0.021), DBP (P=6.0×10(−3)) and mean arterial pressure (MAP) (P=0.021) in the felodipine treatment group of the validation set. As for the reductions influenced by the rs2295490, rs11470129 and rs4815567 genetic variations, however, the adjusted P-value did not reach statistical significance. Combined screening and validation set analysis found that patients with TRIB3 rs6037475 CC genotype had a significant higher mean SBP, DBP and MAP than those with TT genotype in the felodipine treatment group (CC vs. TT −10.2±0.74 vs. −17.8±0.21, P=7.8×10(−3); −4.6±0.50 vs. −10.2±0.23, P=3.0×10(−4); −6.5±0.54 vs. −12.7±0.14, P=3.0×10(−4), respectively). CONCLUSIONS: These results suggest that TRIB3 rs6037475 genetic variation can be useful as a bio-marker for predicting felodipine drug response in Chinese patients with hypertension.
format Online
Article
Text
id pubmed-7210142
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-72101422020-05-11 TRIB3 rs6037475 is a potential biomarker for predicting felodipine drug response in Chinese patients with hypertension He, Fazhong Sun, Bao Li, Ling Liu, Mouze Lin, Weijie Liu, Lin Sun, Yinxiang Luo, Yuhong Wu, Lin Lu, Ligong Zhang, Wei Zhou, Zhiling Ann Transl Med Original Article BACKGROUND: Our previous studies have found that single nucleotide polymorphisms (SNPs) of tribbles homolog 3 (TRIB3) are related to the hypotensive effects of calcium-channel blockers (CCBs) and angiotensin-converting enzyme (ACE) inhibitors. In this study, we aimed at exploring and validating the effect of TRIB3 polymorphism on antihypertensive drugs responses. METHODS: A total of 830 hypertensive patients, who were administered with open-labeled hydrochlorothiazide (12.5 mg once daily) and randomly assigned to off-labeled felodipine (5 mg) or a matched placebo combination treatment (1:1), were selected from the Felodipine Event Reduction (FEVER) study. A strategy of screening 259 samples and validating the remaining 531 samples was implemented. Four functional SNPs were selected (rs2295490, rs11470129, rs4815567 and rs6037475 in TRIB3). A mixed linear model was performed to analyze the effects of TRIB3 SNPs on antihypertensive drugs responses. RESULTS: We found that TRIB3 rs6037475 CC genotype was associated with a reduction of diastolic blood pressure (DBP) (P=6.3×10(−3)) in the felodipine treatment group of screening set, and was also associated with a reduction of systolic blood pressure (SBP) (P=0.021), DBP (P=6.0×10(−3)) and mean arterial pressure (MAP) (P=0.021) in the felodipine treatment group of the validation set. As for the reductions influenced by the rs2295490, rs11470129 and rs4815567 genetic variations, however, the adjusted P-value did not reach statistical significance. Combined screening and validation set analysis found that patients with TRIB3 rs6037475 CC genotype had a significant higher mean SBP, DBP and MAP than those with TT genotype in the felodipine treatment group (CC vs. TT −10.2±0.74 vs. −17.8±0.21, P=7.8×10(−3); −4.6±0.50 vs. −10.2±0.23, P=3.0×10(−4); −6.5±0.54 vs. −12.7±0.14, P=3.0×10(−4), respectively). CONCLUSIONS: These results suggest that TRIB3 rs6037475 genetic variation can be useful as a bio-marker for predicting felodipine drug response in Chinese patients with hypertension. AME Publishing Company 2020-04 /pmc/articles/PMC7210142/ /pubmed/32395481 http://dx.doi.org/10.21037/atm.2020.03.176 Text en 2020 Annals of Translational Medicine. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Original Article
He, Fazhong
Sun, Bao
Li, Ling
Liu, Mouze
Lin, Weijie
Liu, Lin
Sun, Yinxiang
Luo, Yuhong
Wu, Lin
Lu, Ligong
Zhang, Wei
Zhou, Zhiling
TRIB3 rs6037475 is a potential biomarker for predicting felodipine drug response in Chinese patients with hypertension
title TRIB3 rs6037475 is a potential biomarker for predicting felodipine drug response in Chinese patients with hypertension
title_full TRIB3 rs6037475 is a potential biomarker for predicting felodipine drug response in Chinese patients with hypertension
title_fullStr TRIB3 rs6037475 is a potential biomarker for predicting felodipine drug response in Chinese patients with hypertension
title_full_unstemmed TRIB3 rs6037475 is a potential biomarker for predicting felodipine drug response in Chinese patients with hypertension
title_short TRIB3 rs6037475 is a potential biomarker for predicting felodipine drug response in Chinese patients with hypertension
title_sort trib3 rs6037475 is a potential biomarker for predicting felodipine drug response in chinese patients with hypertension
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7210142/
https://www.ncbi.nlm.nih.gov/pubmed/32395481
http://dx.doi.org/10.21037/atm.2020.03.176
work_keys_str_mv AT hefazhong trib3rs6037475isapotentialbiomarkerforpredictingfelodipinedrugresponseinchinesepatientswithhypertension
AT sunbao trib3rs6037475isapotentialbiomarkerforpredictingfelodipinedrugresponseinchinesepatientswithhypertension
AT liling trib3rs6037475isapotentialbiomarkerforpredictingfelodipinedrugresponseinchinesepatientswithhypertension
AT liumouze trib3rs6037475isapotentialbiomarkerforpredictingfelodipinedrugresponseinchinesepatientswithhypertension
AT linweijie trib3rs6037475isapotentialbiomarkerforpredictingfelodipinedrugresponseinchinesepatientswithhypertension
AT liulin trib3rs6037475isapotentialbiomarkerforpredictingfelodipinedrugresponseinchinesepatientswithhypertension
AT sunyinxiang trib3rs6037475isapotentialbiomarkerforpredictingfelodipinedrugresponseinchinesepatientswithhypertension
AT luoyuhong trib3rs6037475isapotentialbiomarkerforpredictingfelodipinedrugresponseinchinesepatientswithhypertension
AT wulin trib3rs6037475isapotentialbiomarkerforpredictingfelodipinedrugresponseinchinesepatientswithhypertension
AT luligong trib3rs6037475isapotentialbiomarkerforpredictingfelodipinedrugresponseinchinesepatientswithhypertension
AT zhangwei trib3rs6037475isapotentialbiomarkerforpredictingfelodipinedrugresponseinchinesepatientswithhypertension
AT zhouzhiling trib3rs6037475isapotentialbiomarkerforpredictingfelodipinedrugresponseinchinesepatientswithhypertension